Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eisai Limited cleared to continue with new sepsis drug trial

Eisai Limited cleared to continue with new sepsis drug trial

26th March 2010

Eisai Limited has received a recommendation from an independent committee to press ahead with a planned phase III trial of a new treatment for sepsis.

A data monitoring committee has analysed safety and efficacy data from the first 1,500 patients enrolled by Eisai for the Access trial, finding no concerns that would necessitate halting the study.

As a result, Eisai has now been cleared to continue enrolment up to the predetermined goal of 2,000 patients.

It is hoped that the trial will support the company’s development of its eritoran endotoxin treatment, which helps to suppress sepsis by inhibiting the release of inflammatory cytokines.

The company said: “Eisai is pursuing the clinical development of eritoran with the aim of addressing the unmet medical needs of severe sepsis patients for whom the mortality rate is very high.”

Earlier this month, Eisai began construction of a new pilot biologics manufacturing plant which will bolster the company’s antibody development programmes when it opens in 2012.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.